NEO Stock Analysis

NeoGenomics Inc (NEO): A Detailed StockValueFinder Educational Review

Overview of NeoGenomics Inc (NEO)

NeoGenomics Inc (NEO) operates in the healthcare sector, specifically within the diagnostics and research industry. The company provides clinical laboratory services, including cancer genetics testing and information services. This StockValueFinder educational review examines NEO using clear, factual metrics to help investors understand how to evaluate stocks systematically.

This article is not a recommendation to buy or sell NEO. Instead, it demonstrates how StockValueFinder applies disciplined financial screening to assess a company’s financial health, efficiency, and valuation. The goal is to help readers learn how to interpret key financial metrics when researching stocks independently.

Why the StockValueFinder Score Matters

StockValueFinder assigns NEO a score of 43% and a rating of **AVOID**. This score reflects a systematic evaluation of the company’s financial strength, efficiency, and valuation based on the supplied metrics. A score below 50% typically indicates that the stock does not meet the platform’s minimum quality standards for financial health, profitability, or valuation discipline.

The 43% score suggests that NEO has significant weaknesses in key areas, such as earnings consistency, capital efficiency, and financial safety. While the company passed one valuation test, the overall financial profile raises concerns. This article will break down each metric to explain why NEO received this score and what investors should consider when evaluating similar stocks.

EPS Strength and Consistency

What Is EPS and Why Does It Matter?

Earnings per share (EPS) measures a company’s profitability on a per-share basis. Consistent and growing EPS over time is generally a sign of a stable, well-managed business. StockValueFinder evaluates EPS strength to assess whether a company has demonstrated reliable earnings performance, which is critical for long-term investment decisions.

StockValueFinder’s EPS Test for NEO

The supplied data indicates that NEO **did not pass** the EPS test. While exact EPS values are not provided, the system’s failure suggests that the company’s earnings history may be inconsistent, negative, or declining. For context, a strong EPS profile typically includes: - Positive EPS in at least 4 of the last 5 years. - Year-over-year EPS growth in most reporting periods. - Minimal volatility in earnings, indicating operational stability.

A company that fails the EPS test may be experiencing financial distress, competitive pressures, or operational inefficiencies. For example, if a company reported EPS of $1.20, $0.80, -$0.50, $0.30, and $0.10 over the last five years, it would likely fail the EPS test due to inconsistency and negative earnings in one year.

Why NEO’s EPS Test Result Matters

NEO’s failure to pass the EPS test is a red flag for investors. Without consistent earnings, it becomes difficult to assess the company’s true profitability or predict future performance. Investors should approach stocks with weak EPS histories cautiously, as they may be more vulnerable to economic downturns or industry disruptions.

ROIC and Capital Efficiency

What Is ROIC?

Return on invested capital (ROIC) measures how effectively a company uses its capital to generate profits. It is calculated as:

**ROIC = (Net Operating Profit After Tax) / (Total Invested Capital)**

A high ROIC indicates that a company is generating strong returns from its investments, while a low or negative ROIC suggests inefficiency or poor capital allocation.

StockValueFinder’s ROIC Benchmark

StockValueFinder generally prefers companies with an ROIC of **10% or higher**. This threshold indicates that the company is generating sufficient returns to justify its capital investments. For example: - A company with an ROIC of 15% is typically more efficient than one with an ROIC of 4%. - An ROIC of 20% or higher is often seen in high-quality businesses with strong competitive advantages.

NEO’s ROIC: -8.25%

NEO’s ROIC is **-8.25%**, which is well below the preferred 10% threshold. This negative ROIC indicates that the company is not generating enough profit to cover its capital costs. In practical terms, a negative ROIC means that for every dollar invested in the business, NEO is losing money rather than earning a return.

Why NEO Failed the ROIC Test

NEO’s negative ROIC is a significant concern. Companies with negative ROIC often struggle with: - High operating costs relative to revenue. - Inefficient use of capital, such as overinvestment in unprofitable projects. - Weak pricing power or competitive pressures.

For comparison, a company with a 12% ROIC is generally considered more financially healthy than one with a -8.25% ROIC. Investors should be cautious about companies with negative ROIC, as they may face challenges in sustaining operations or funding growth without external financing.

Interest Coverage and Financial Safety

What Is Interest Coverage?

Interest coverage measures a company’s ability to pay interest on its debt. It is calculated as:

**Interest Coverage = (Earnings Before Interest and Taxes) / (Interest Expense)**

A higher interest coverage ratio indicates greater financial safety, as the company can comfortably meet its debt obligations. A low or negative ratio suggests that the company may struggle to service its debt, increasing the risk of default.

StockValueFinder’s Interest Coverage Benchmark

StockValueFinder prefers companies with an interest coverage ratio of **6 or higher**. This threshold ensures that the company has a sufficient buffer to cover interest payments even if earnings decline. For example: - A company with an interest coverage ratio of 8x is in a stronger financial position than one with a ratio of 2x. - A ratio below 1x indicates that the company is not generating enough earnings to cover its interest expenses.

NEO’s Interest Coverage Test Result

The supplied data indicates that NEO **did not pass** the interest coverage test. While the exact interest coverage ratio is not provided, the failure suggests that the company’s earnings may be insufficient to cover its interest expenses. This is a red flag for financial safety, as it indicates potential liquidity risks or overleveraging.

Why NEO’s Interest Coverage Test Result Matters

Companies that fail the interest coverage test may face challenges such as

Investors should approach companies with weak interest coverage cautiously, as they may be more vulnerable to financial distress.

Debt Payback and Balance Sheet Discipline

What Is Debt Payback?

Debt payback measures how long it would take a company to pay off its total debt using its current operating cash flow. It is calculated as:

**Debt Payback (Years) = (Total Debt) / (Operating Cash Flow)**

A shorter debt payback period indicates a stronger balance sheet and greater financial flexibility. A longer or negative debt payback period suggests that the company may be overleveraged or struggling to generate sufficient cash flow.

StockValueFinder’s Debt Payback Benchmark

StockValueFinder prefers companies with a debt payback period of **3 years or less**. This threshold ensures that the company can quickly reduce its debt burden and avoid excessive interest expenses. For example: - A company with a debt payback period of 1.5 years is in a stronger position than one with a 7-year payback period. - A negative debt payback period indicates that the company is not generating positive operating cash flow, which is a significant red flag.

NEO’s Debt Payback: -15.70 Years

NEO’s debt payback period is **-15.70 years**, which is well below the preferred threshold. A negative debt payback period indicates that the company is not generating enough operating cash flow to cover its debt obligations. This is a critical weakness, as it suggests that NEO may struggle to service its debt without relying on external financing or asset sales.

Why NEO Passed the Debt Payback Test (Despite the Negative Number)

Interestingly, NEO **passed** the debt payback test in StockValueFinder’s system. This may seem counterintuitive given the negative payback period, but it likely reflects the platform’s methodology for handling edge cases. For example: - The system may classify negative debt payback as a "pass" if the company has no debt or if the metric is not applicable (e.g., for companies with no operating cash flow). - Alternatively, the system may prioritize other balance sheet metrics, such as liquidity ratios, over debt payback in certain cases.

However, investors should not interpret this as a positive signal. A negative debt payback period is a serious concern and indicates that NEO’s balance sheet is weak. Companies with negative debt payback periods often face: - High risk of default or bankruptcy. - Limited ability to invest in growth or innovation. - Dependence on external financing, which can be costly or unavailable during economic downturns.

P/E Ratio and Valuation Discipline

What Is the P/E Ratio?

The price-to-earnings (P/E) ratio measures a company’s stock price relative to its earnings per share. It is calculated as:

**P/E Ratio = (Stock Price) / (Earnings Per Share)**

A lower P/E ratio may indicate that a stock is undervalued, while a higher P/E ratio may suggest overvaluation. However, the P/E ratio must be interpreted in the context of the company’s growth prospects, industry norms, and overall financial health.

StockValueFinder’s P/E Benchmark

StockValueFinder prefers companies with a P/E ratio of **15 or lower** for valuation discipline. This threshold helps investors avoid overpaying for stocks, particularly in industries with high growth expectations. For example: - A P/E ratio of 8 may indicate better value than a P/E ratio of 40, assuming the company’s earnings are stable and growing. - A negative P/E ratio indicates that the company is not profitable, which is a significant red flag.

NEO’s P/E Ratio: -198.68

NEO’s P/E ratio is **-198.68**, which is well below the preferred threshold of 15. However, this negative P/E ratio indicates that the company is not profitable. A negative P/E ratio occurs when a company reports negative earnings, meaning it is losing money rather than generating profits.

Why NEO Passed the P/E Valuation Test

Despite the negative P/E ratio, NEO **passed** the P/E valuation test in StockValueFinder’s system. This may seem unusual, but it likely reflects the platform’s methodology for handling unprofitable companies. For example: - The system may classify negative P/E ratios as a "pass" if the company is in a high-growth industry where profitability is expected to improve in the future. - Alternatively, the system may prioritize other valuation metrics, such as enterprise value-to-EBITDA, over P/E for unprofitable companies.

However, investors should not interpret this as a positive signal. A negative P/E ratio is a significant concern and indicates that NEO is not generating profits. Companies with negative P/E ratios often face: - High risk of financial distress or bankruptcy. - Limited ability to reinvest in the business or return value to shareholders. - Dependence on external financing to sustain operations.

Moving Average Trend and Entry Timing

What Is the Moving Average Signal?

The moving average signal is a technical indicator that helps investors assess a stock’s trend. It compares the stock’s current price to its moving average (e.g., 50-day or 200-day) to determine whether the trend is bullish, bearish, or neutral. While moving averages are not predictive, they can provide insights into market sentiment and potential entry or exit points.

StockValueFinder’s Moving Average Signal for NEO

NEO’s moving average signal is **NEUTRAL / WATCH**, and the entry signal is **N/A**. This indicates that the stock is not exhibiting a clear bullish or bearish trend based on its moving averages. A neutral signal suggests that the stock may be range-bound or consolidating, rather than trending strongly in either direction.

Why the Moving Average Signal Matters

The moving average signal is a tool for timing discipline, not a guarantee of future performance. For example: - A bullish signal (e.g., price above the 200-day moving average) may indicate that the stock is in an uptrend, but it does not guarantee that the trend will continue. - A bearish signal (e.g., price below the 200-day moving average) may indicate that the stock is in a downtrend, but it does not guarantee that the trend will persist.

NEO’s neutral signal suggests that investors should exercise caution and avoid making decisions based solely on trend analysis. Instead, they should focus on the company’s fundamentals, such as earnings, ROIC, and debt levels.

Overall Financial Strengths and Weaknesses

Strengths

1. **Passed the P/E Valuation Test**: While NEO’s P/E ratio is negative, the system’s classification of this as a "pass" may reflect the platform’s methodology for handling unprofitable companies. However, investors should not interpret this as a positive signal. 2. **Passed the Debt Payback Test**: Despite the negative debt payback period, the system’s classification of this as a "pass" may reflect edge-case handling. Again, this should not be interpreted as a strength.

Weaknesses

1. **Failed the EPS Test**: NEO’s inconsistent or negative earnings history is a significant concern, as it indicates potential financial instability. 2. **Negative ROIC (-8.25%)**: The company is not generating sufficient returns on its invested capital, suggesting inefficiency or poor capital allocation. 3. **Failed the Interest Coverage Test**: NEO’s inability to cover its interest expenses raises concerns about financial safety and debt sustainability. 4. **Negative P/E Ratio (-198.68)**: The company is not profitable, which is a critical weakness for long-term investors. 5. **Negative Debt Payback Period (-15.70 Years)**: NEO is not generating enough operating cash flow to cover its debt obligations, indicating a weak balance sheet.

Risks and Limitations

Financial Risks

1. **Negative Earnings and Cash Flow**: NEO’s negative earnings and cash flow raise concerns about its ability to sustain operations without external financing. 2. **High Debt Levels**: The company’s negative debt payback period suggests that it may be overleveraged, increasing the risk of default or bankruptcy. 3. **Low ROIC**: NEO’s negative ROIC indicates that it is not generating sufficient returns on its capital investments, which could limit its ability to grow or innovate.

Industry Risks

1. **Competitive Pressures**: The diagnostics and research industry is highly competitive, with companies facing pressure to innovate and reduce costs. NEO’s financial weaknesses may limit its ability to compete effectively. 2. **Regulatory Risks**: Healthcare companies are subject to strict regulatory oversight, which can increase compliance costs and operational complexity. 3. **Technological Disruption**: Rapid advancements in diagnostic technologies could disrupt NEO’s business model or render its services obsolete.

Limitations of This Analysis

1. **Incomplete Data**: This article is based on the supplied metrics, which may not include all relevant financial data (e.g., detailed EPS history, cash flow statements, or balance sheet items). 2. **No Forward-Looking Analysis**: This review focuses on historical and current financial metrics. It does not account for potential future improvements in NEO’s operations or industry trends. 3. **No Qualitative Factors**: This analysis does not consider qualitative factors, such as management quality, competitive advantages, or industry tailwinds, which can also impact a company’s performance.

Educational Conclusion

This StockValueFinder educational review of NeoGenomics Inc (NEO) demonstrates how to evaluate a stock using disciplined financial metrics. NEO’s score of 43% and rating of **AVOID** reflect significant weaknesses in key areas, including earnings consistency, capital efficiency, and financial safety.

Key Takeaways for Investors

1. **EPS Consistency Matters**: Companies with inconsistent or negative earnings are often riskier investments. NEO’s failure to pass the EPS test highlights the importance of evaluating earnings stability. 2. **ROIC Indicates Efficiency**: A negative ROIC, like NEO’s -8.25%, suggests that a company is not generating sufficient returns on its capital. Investors should prioritize companies with ROIC of 10% or higher. 3. **Interest Coverage Reflects Financial Safety**: Companies that fail the interest coverage test may struggle to service their debt, increasing the risk of financial distress. NEO’s failure in this area is a red flag. 4. **Debt Payback Signals Balance Sheet Health**: A negative debt payback period, like NEO’s -15.70 years, indicates that a company is not generating enough cash flow to cover its debt. This is a critical weakness. 5. **P/E Ratio Must Be Interpreted Carefully**: While NEO passed the P/E valuation test, its negative P/E ratio of -198.68 indicates that the company is not profitable. Investors should not rely solely on P/E for valuation. 6. **Moving Averages Are for Timing, Not Prediction**: NEO’s neutral moving average signal suggests that the stock is not exhibiting a clear trend. Investors should use trend analysis as one tool among many, not as a guarantee of future performance.

How to Apply This Analysis to Other Stocks

When evaluating stocks, investors should

1. **Assess Earnings Consistency**: Look for companies with positive and growing EPS over time. 2. **Evaluate Capital Efficiency**: Prioritize companies with ROIC of 10% or higher. 3. **Check Financial Safety**: Ensure that companies have sufficient interest coverage (6x or higher) and manageable debt levels (debt payback of 3 years or less). 4. **Consider Valuation**: Use P/E ratios and other valuation metrics to avoid overpaying for stocks, but interpret them in the context of the company’s financial health. 5. **Monitor Trends**: Use moving averages and other technical indicators to assess market sentiment, but do not rely on them exclusively.

Final Thoughts

NeoGenomics Inc (NEO) presents significant financial challenges, as reflected in its low StockValueFinder score and rating. While the company operates in the growing healthcare diagnostics industry, its weak fundamentals—including negative earnings, negative ROIC, and high debt levels—make it a high-risk investment.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings